| Title | Comparison of Antiemetic Efficacy between Single and Repeated Treatments with a 5-HT3 Receptor Antagonist in Breast Cancer Patients with High-risk Emetogenic Chemotherapy. | | Author(s) | Taguchi K, Iihara H, Ishihara M, Komori Y, Tanizawa K, Matsuura K, Itoh Y | | Institution | Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu 501-1194, Japan. yositou@gifu-u.ac.jp. | | Source | Anticancer Res 2009 May; 29(5):1721-5. | | Abstract | BACKGROUND: The significance of repeated treatment with the 5-HT(3) receptor antagonist for prophylaxis of chemotherapy-induced emesis remains to be clarified.
PATIENTS AND METHODS: A retrospective analysis was performed to compare the effects of single and repeated treatment with granisetron on anorexia, nausea and vomiting in patients with breast cancer who undertook anthracycline and cyclophosphamide-based cancer chemotherapy.
RESULTS: The control of anorexia was significantly better in the single treatment group than in the repeated treatment group (54% versus 73%; odds ratio (OR), 0.433; 95% confidence intervals (CI), 0.226-0.828; p=0.016), although the rate of complete response to any signs of the gastrointestinal side-effects was not different between the two groups (37% versus 39%; OR, 0.911; CI, 0.489-1.700; p=0.874). However, the incidence of constipation was more frequent in the repeated treatment group (60% versus 37%; OR, 2.586; CI, 1.388-4.818; p=0.003).
CONCLUSION: Repeated treatment with 5-HT(3) receptor antagonist is not likely to be beneficial to breast cancer patients who undertook anthracycline/cyclophosphamide combination chemotherapy. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19443393 |
|
